EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00041028 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: EF5
OTHER: flow cytometry
OTHER: immunohistochemistry staining method

Sponsor

Duke University

Collaborators

[object Object]